Showing results (1021-1030 of 3,103) with videos related to

Sort By:
Pageof 311
Drug Safety|January 1, 1992
Mechanisms of clozapine-induced agranulocytosisS L Gerson, H Meltzer
Drug Safety|January 1, 1992
No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosisF H Claas, P A Abbott, M D Witvliet, et al.
Drug Safety|February 6, 2004
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribingRashmi R Shah
Drug Safety|February 6, 2004
Benefit-risk assessment of rofecoxib in the treatment of osteoarthritisHelmut Schmidt, Barry G Woodcock, Gerd Geisslinger
Drug Safety|July 1, 1992
Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteersM C Chapelsky, D E Nix, J C Cavanaugh, et al.
Drug Safety|June 27, 2003
Paediatric medicines research in the UK: how to move forward?Ian Wong, Dimah Sweis, Judith Cope, et al.
Drug Safety|June 27, 2003
'Atypical' antidepressants in overdose: clinical considerations with respect to safetyNicholas A Buckley, Thomas A Faunce
Drug Safety|June 27, 2003
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamineGeorge J Kontoghiorghes, Katia Neocleous, Annita Kolnagou
Drug Safety|March 1, 2003
Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomitingAnthony L Kovac
Drug Safety|March 1, 2003
Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infectionThierry Lacaze-Masmonteil, Juergen Seidenberg, Ian Mitchell, et al.
Pageof 311